Next Article in Journal
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Previous Article in Journal
Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Lee et al. Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. Cancers 2022, 14, 2659

1
Department of Internal Medicine, Division of Medical Oncology, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul 03312, Republic of Korea
2
Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea
3
Department of Internal Medicine, Division of Hospital Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
4
Department of Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
5
Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
6
Department of Surgery, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
7
Yonsei Cancer Center, Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
8
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors contributed equally as corresponding authors.
Cancers 2022, 14(22), 5658; https://doi.org/10.3390/cancers14225658
Submission received: 16 September 2022 / Accepted: 7 October 2022 / Published: 17 November 2022
In the original article [1], there was a mistake in Table 1 as published. There were two tumors with tumor size ≤ 5 cm in the NTRK fusion group (n = 5); however, there were three tumors with tumor size ≤ 5 cm in the five cases in Table 3. Moreover, patients 0 and 1 were low- and intermediate-risk of metastasis, respectively, in Table 1, which was not consistent with the results in Table 3. The corrected Table 1 appears below. Modified numbers are red-colored.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.

Reference

  1. Lee, J.H.; Shin, S.-J.; Choe, E.-A.; Kim, J.; Hyung, W.J.; Kim, H.S.; Jung, M.; Beom, S.-H.; Kim, T.I.; Ahn, J.B.; et al. Tropomyosin-related kinase fusions in gastrointestinal stromal tumors. Cancers 2022, 14, 2659. [Google Scholar] [CrossRef] [PubMed]
Table 1. Baseline characteristics.
Table 1. Baseline characteristics.
CharacteristicsTotal (n = 31) N (%)NTRK Fusion (n = 5)NTRK Wild Type (n = 26)p-Value
Age
Median (range)56 (33–92)61 (33–92)53 (37–84)0.163
Sex---1000
Male14 (45.2)2 (40.0)12 (46.2)-
Female17 (54.8)3 (60.0)14 (53.8)-
Tumor size (cm)----
Median ± SD8.2 ± 5.33.9 ± 6.56.0 ± 5.20.410
Tumor location---0.028
Abdominal wall1 (0.3)0 (0.0)1 (3.8)-
Stomach14 (45.1)1 (20.0)14 (53.8)-
Small bowel11 (35.4)2 (40.0)6 (23.1)-
Descending colon1 (0.3)0 (0.0)1 (3.8)-
Rectum4 (12.9)2 (40.0)4 (15.4)-
Tumor size, groups (cm) ---1000
≤514 (50.0)3 (60.0)11 (47.8)-
>514 (50.0)2 (40.0)12 (52.2)--
Mitotic rate (no. of mitoses/50 HPFs *)---0.711
≤511 (50.0)2 (40.0)12 (52.2)-
>516 (50.0)3 (60.0)10 (43.5)-
Disease status---0.859
No evidence of disease21 (67.7)5 (100.0)16 (61.5)-
on anticancer treatment3 (9.7)0 (0.0)3 (11.5)-
Unknown3 (9.7)0 (0.0)3 (11.5)-
Dead4 (12.9)0 (0.0)4 (15.4)-
Risk of metastasis ---0.253
Low8 (25.8)1 (20.0)7 (26.9)-
Intermediate3 (9.7)0 (0.0)3 (11.5)-
High17 (54.8)4 (80.0)13 (50.0)-
Not assessable3 (9.7)0 (0.0)3 (11.5)-
Surgical treatment---1000
Yes28 (90.3)5 (100.0)23 (88.5)-
No3 (9.7)0 (0.0)3 (11.5)-
For three inoperable cases, size information and mitotic rate are missing because there was no surgical specimen. Mitotic rate was not evaluated in one surgical specimen. Risk of metastasis was evaluated according to the National Institute of Health (NIH) classification. HPFs: high-power fields; * per 50 HPFs is a total of 5 mm2.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lee, J.H.; Shin, S.-J.; Choe, E.-A.; Kim, J.; Hyung, W.J.; Kim, H.S.; Jung, M.; Beom, S.-H.; Kim, T.I.; Ahn, J.B.; et al. Correction: Lee et al. Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. Cancers 2022, 14, 2659. Cancers 2022, 14, 5658. https://doi.org/10.3390/cancers14225658

AMA Style

Lee JH, Shin S-J, Choe E-A, Kim J, Hyung WJ, Kim HS, Jung M, Beom S-H, Kim TI, Ahn JB, et al. Correction: Lee et al. Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. Cancers 2022, 14, 2659. Cancers. 2022; 14(22):5658. https://doi.org/10.3390/cancers14225658

Chicago/Turabian Style

Lee, Ji Hyun, Su-Jin Shin, Eun-Ah Choe, Jungyoun Kim, Woo Jin Hyung, Hyo Song Kim, Minkyu Jung, Seung-Hoon Beom, Tae Il Kim, Joong Bae Ahn, and et al. 2022. "Correction: Lee et al. Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. Cancers 2022, 14, 2659" Cancers 14, no. 22: 5658. https://doi.org/10.3390/cancers14225658

APA Style

Lee, J. H., Shin, S. -J., Choe, E. -A., Kim, J., Hyung, W. J., Kim, H. S., Jung, M., Beom, S. -H., Kim, T. I., Ahn, J. B., Chung, H. C., & Shin, S. J. (2022). Correction: Lee et al. Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. Cancers 2022, 14, 2659. Cancers, 14(22), 5658. https://doi.org/10.3390/cancers14225658

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop